1
|
Vaz FM, Staps P, van Klinken JB, van Lenthe H, Vervaart M, Wanders RJA, Pras-Raves ML, van Weeghel M, Salomons GS, Ferdinandusse S, Wevers RA, Willemsen MAAP. Discovery of novel diagnostic biomarkers for Sjögren-Larsson syndrome by untargeted lipidomics. Biochim Biophys Acta Mol Cell Biol Lipids 2024; 1869:159447. [PMID: 38181883 DOI: 10.1016/j.bbalip.2023.159447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Revised: 12/02/2023] [Accepted: 12/05/2023] [Indexed: 01/07/2024]
Abstract
AIM Sjögren-Larsson syndrome (SLS) is a rare neurometabolic disorder that mainly affects brain, eye and skin and is caused by deficiency of fatty aldehyde dehydrogenase. Our recent finding of a profoundly disturbed brain tissue lipidome in SLS prompted us to search for similar biomarkers in plasma as no functional test in blood is available for SLS. METHODS AND RESULTS We performed plasma lipidomics and used a newly developed bioinformatics tool to mine the untargeted part of the SLS plasma and brain lipidome to search for SLS biomarkers. Plasma lipidomics showed disturbed ether lipid metabolism in known lipid classes. Untargeted lipidomics of both plasma and brain (white and grey matter) uncovered two new endogenous lipid classes highly elevated in SLS. The first biomarker group were alkylphosphocholines/ethanolamines containing different lengths of alkyl-chains where some alkylphosphocholines were > 600-fold elevated in SLS plasma. The second group of biomarkers were a set of 5 features of unknown structure. Fragmentation studies suggested that they contain ubiquinol and phosphocholine and one feature was also found as a glucuronide conjugate in plasma. The plasma features were highly distinctive for SLS with levels >100-1000-fold the level in controls, if present at all. We speculate on the origin of the alkylphosphocholines/ethanolamines and the nature of the ubiquinol-containing metabolites. CONCLUSIONS The metabolites identified in this study represent novel endogenous lipid classes thus far unknown in humans. They represent the first plasma metabolite SLS-biomarkers and may also yield more insight into SLS pathophysiology.
Collapse
Affiliation(s)
- Frédéric M Vaz
- Amsterdam UMC location University of Amsterdam, Departments of Laboratory Medicine and Pediatrics, Laboratory Genetic Metabolic Diseases, Emma Children's Hospital, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Gastroenterology Endocrinology Metabolism, Inborn errors of metabolism, Amsterdam, the Netherlands; Core Facility Metabolomics, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands; United for Metabolic Diseases, the Netherlands.
| | - Pippa Staps
- Department of Pediatric Neurology, Radboud University Medical Center, Amalia Children's Hospital, Donders Institute for Brain Cognition and Behaviour, Nijmegen, the Netherlands
| | - Jan Bert van Klinken
- Amsterdam UMC location University of Amsterdam, Departments of Laboratory Medicine and Pediatrics, Laboratory Genetic Metabolic Diseases, Emma Children's Hospital, Meibergdreef 9, Amsterdam, the Netherlands; Core Facility Metabolomics, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands; Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands
| | - Henk van Lenthe
- Amsterdam UMC location University of Amsterdam, Departments of Laboratory Medicine and Pediatrics, Laboratory Genetic Metabolic Diseases, Emma Children's Hospital, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Gastroenterology Endocrinology Metabolism, Inborn errors of metabolism, Amsterdam, the Netherlands; Core Facility Metabolomics, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands
| | - Martin Vervaart
- Amsterdam UMC location University of Amsterdam, Departments of Laboratory Medicine and Pediatrics, Laboratory Genetic Metabolic Diseases, Emma Children's Hospital, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Gastroenterology Endocrinology Metabolism, Inborn errors of metabolism, Amsterdam, the Netherlands; Core Facility Metabolomics, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands
| | - Ronald J A Wanders
- Amsterdam UMC location University of Amsterdam, Departments of Laboratory Medicine and Pediatrics, Laboratory Genetic Metabolic Diseases, Emma Children's Hospital, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Gastroenterology Endocrinology Metabolism, Inborn errors of metabolism, Amsterdam, the Netherlands; United for Metabolic Diseases, the Netherlands
| | - Mia L Pras-Raves
- Amsterdam UMC location University of Amsterdam, Departments of Laboratory Medicine and Pediatrics, Laboratory Genetic Metabolic Diseases, Emma Children's Hospital, Meibergdreef 9, Amsterdam, the Netherlands; Core Facility Metabolomics, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands; Bioinformatics Laboratory, Department of Epidemiology & Data Science, Amsterdam Public Health Research Institute, Amsterdam UMC, University of Amsterdam, the Netherlands
| | - Michel van Weeghel
- Amsterdam UMC location University of Amsterdam, Departments of Laboratory Medicine and Pediatrics, Laboratory Genetic Metabolic Diseases, Emma Children's Hospital, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Gastroenterology Endocrinology Metabolism, Inborn errors of metabolism, Amsterdam, the Netherlands; Core Facility Metabolomics, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands
| | - Gajja S Salomons
- Amsterdam UMC location University of Amsterdam, Departments of Laboratory Medicine and Pediatrics, Laboratory Genetic Metabolic Diseases, Emma Children's Hospital, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Gastroenterology Endocrinology Metabolism, Inborn errors of metabolism, Amsterdam, the Netherlands; Core Facility Metabolomics, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands; United for Metabolic Diseases, the Netherlands
| | - Sacha Ferdinandusse
- Amsterdam UMC location University of Amsterdam, Departments of Laboratory Medicine and Pediatrics, Laboratory Genetic Metabolic Diseases, Emma Children's Hospital, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Gastroenterology Endocrinology Metabolism, Inborn errors of metabolism, Amsterdam, the Netherlands; United for Metabolic Diseases, the Netherlands
| | - Ron A Wevers
- United for Metabolic Diseases, the Netherlands; Department of Human Genetics, Donders Institute for Brain Cognition and Behaviour, Translational Metabolic Laboratory, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Michèl A A P Willemsen
- United for Metabolic Diseases, the Netherlands; Department of Pediatric Neurology, Radboud University Medical Center, Amalia Children's Hospital, Donders Institute for Brain Cognition and Behaviour, Nijmegen, the Netherlands
| |
Collapse
|
2
|
Roussaki M, Magoulas GE, Fotopoulou T, Santarem N, Barrias E, Pöhner I, Luelmo S, Afroudakis P, Georgikopoulou K, Nevado PT, Eick J, Bifeld E, Corral MJ, Jiménez-Antón MD, Ellinger B, Kuzikov M, Fragiadaki I, Scoulica E, Gul S, Clos J, Prousis KC, Torrado JJ, Alunda JM, Wade RC, de Souza W, Cordeiro da Silva A, Calogeropoulou T. Design, synthesis and biological evaluation of antiparasitic dinitroaniline-ether phospholipid hybrids. Bioorg Chem 2023; 138:106615. [PMID: 37244229 DOI: 10.1016/j.bioorg.2023.106615] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2023] [Revised: 05/05/2023] [Accepted: 05/15/2023] [Indexed: 05/29/2023]
Abstract
A series of nine novel ether phospholipid-dinitroaniline hybrids were synthesized in an effort to deliver more potent antiparasitic agents with improved safety profile compared to miltefosine. The compounds were evaluated for their in vitro antiparasitic activity against L. infantum, L.donovani, L. amazonensis, L. major and L. tropica promastigotes, L. infantum and L. donovani intracellular amastigotes, Trypanosoma brucei brucei and against different developmental stages of Trypanosoma cruzi. The nature of the oligomethylene spacer between the dinitroaniline moiety and the phosphate group, the length of the side chain substituent on the dinitroaniline and the choline or homocholine head group were found to affect both the activity and toxicity of the hybrids. The early ADMET profile of the derivatives did not reveal major liabilities. Hybrid 3, bearing an 11-carbon oligomethylene spacer, a butyl side chain and a choline head group, was the most potent analogue of the series. It exhibited a broad spectrum antiparasitic profile against the promastigotes of New and Old World Leishmania spp., against intracellular amastigotes of two L. infantum strains and L. donovani, against T. brucei and against T. cruzi Y strain epimastigotes, intracellular amastigotes and trypomastigotes. The early toxicity studies revealed that hybrid 3 showed a safe toxicological profile while its cytotoxicity concentration (CC50) against THP-1 macrophages being >100 μM. Computational analysis of binding sites and docking indicated that the interaction of hybrid 3 with trypanosomatid α-tubulin may contribute to its mechanism of action. Furthermore, compound 3 was found to interfere with the cell cycle in T. cruzi epimastigotes, while ultrastructural studies using SEM and TEM in T. cruzi showed that compound 3 affects cellular processes that result in changes in the Golgi complex, the mitochondria and the parasite's plasma membrane. The snapshot pharmacokinetic studies showed low levels of 3 after 24 h following oral administration of 100 mg/Kg, while, its homocholine congener compound 9 presented a better pharmacokinetic profile.
Collapse
Affiliation(s)
- Marina Roussaki
- National Hellenic Research Foundation, Institute of Chemical Biology, 48 Vassileos Constantinou Avenue, 11635 Athens, Greece.
| | - George E Magoulas
- National Hellenic Research Foundation, Institute of Chemical Biology, 48 Vassileos Constantinou Avenue, 11635 Athens, Greece.
| | - Theano Fotopoulou
- National Hellenic Research Foundation, Institute of Chemical Biology, 48 Vassileos Constantinou Avenue, 11635 Athens, Greece.
| | - Nuno Santarem
- i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; IBMC-Instituto de Biologia Molecular e Celular, Parasite Disease Group, Porto, Portugal.
| | - Emile Barrias
- Instituto Nacional de Ciência e Tecnologia em Biologia Estrutural e Bioimagens, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Avenida Carlos Chagas Filho s/n, Ilha do Fundão, 21941-900 Rio de Janeiro, Brazil.
| | - Ina Pöhner
- School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
| | - Sara Luelmo
- i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
| | - Pantelis Afroudakis
- National Hellenic Research Foundation, Institute of Chemical Biology, 48 Vassileos Constantinou Avenue, 11635 Athens, Greece.
| | - Kalliopi Georgikopoulou
- National Hellenic Research Foundation, Institute of Chemical Biology, 48 Vassileos Constantinou Avenue, 11635 Athens, Greece.
| | - Paloma Tejera Nevado
- Bernhard Nocht Institute for Tropical Medicine, Leishmania Genetics Group, Bernhard Nocht St 74, D-20359 Hamburg, Germany.
| | - Julia Eick
- Bernhard Nocht Institute for Tropical Medicine, Leishmania Genetics Group, Bernhard Nocht St 74, D-20359 Hamburg, Germany.
| | - Eugenia Bifeld
- Bernhard Nocht Institute for Tropical Medicine, Leishmania Genetics Group, Bernhard Nocht St 74, D-20359 Hamburg, Germany.
| | - María J Corral
- Department of Animal Health, Faculty of Veterinary Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain.
| | - María Dolores Jiménez-Antón
- Department of Animal Health, Faculty of Veterinary Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain.
| | - Bernhard Ellinger
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Hamburg, Germany; Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD, Hamburg, Germany.
| | - Maria Kuzikov
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Hamburg, Germany; Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD, Hamburg, Germany.
| | - Irini Fragiadaki
- University of Crete, Faculty of Medicine, Department of Clinical Microbiology and Microbial Pathogenesis, Voutes University Campus, 70013 Heraklion, Crete, Greece.
| | - Effie Scoulica
- University of Crete, Faculty of Medicine, Department of Clinical Microbiology and Microbial Pathogenesis, Voutes University Campus, 70013 Heraklion, Crete, Greece.
| | - Sheraz Gul
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Hamburg, Germany; Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD, Hamburg, Germany.
| | - Joachim Clos
- Bernhard Nocht Institute for Tropical Medicine, Leishmania Genetics Group, Bernhard Nocht St 74, D-20359 Hamburg, Germany.
| | - Kyriakos C Prousis
- National Hellenic Research Foundation, Institute of Chemical Biology, 48 Vassileos Constantinou Avenue, 11635 Athens, Greece.
| | - Juan J Torrado
- Department of Pharmaceutics and Food Technology, Complutense University of Madrid, 28240 Madrid, Spain.
| | - José María Alunda
- Department of Animal Health, Faculty of Veterinary Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain.
| | - Rebecca C Wade
- Molecular and Cellular Modeling Group, Heidelberg Institute for Theoretical Studies (HITS), D-69118 Heidelberg, Germany; Center for Molecular Biology (ZMBH), DKFZ-ZMBH Alliance, and Interdisciplinary Center for Scientific Computing (IWR), Heidelberg University, D-69120 Heidelberg, Germany.
| | - Wanderley de Souza
- Instituto Nacional de Ciência e Tecnologia em Biologia Estrutural e Bioimagens, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Avenida Carlos Chagas Filho s/n, Ilha do Fundão, 21941-900 Rio de Janeiro, Brazil.
| | - Anabela Cordeiro da Silva
- IBMC-Instituto de Biologia Molecular e Celular, Parasite Disease Group, Porto, Portugal; Instituto Nacional de Ciência e Tecnologia em Biologia Estrutural e Bioimagens, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Departmento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal.
| | - Theodora Calogeropoulou
- National Hellenic Research Foundation, Institute of Chemical Biology, 48 Vassileos Constantinou Avenue, 11635 Athens, Greece.
| |
Collapse
|
3
|
Wnętrzak A, Łątka K, Makyła-Juzak K, Zemla J, Dynarowicz-Łątka P. The influence of an antitumor lipid - erucylphosphocholine - on artificial lipid raft system modeled as Langmuir monolayer. Mol Membr Biol 2016; 32:189-97. [PMID: 26911703 DOI: 10.3109/09687688.2015.1125537] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Outer layer of cellular membrane contains ordered domains enriched in cholesterol and sphingolipids, called 'lipid rafts', which play various biological roles, i.e., are involved in the induction of cell death by apoptosis. Recent studies have shown that these domains may constitute binding sites for selected drugs. For example alkylphosphocholines (APCs), which are new-generation antitumor agents characterized by high selectivity and broad spectrum of activity, are known to have their molecular targets located at cellular membrane and their selective accumulation in tumor cells has been hypothesized to be linked with the alternation of biophysical properties of lipid rafts. To get a deeper insight into this issue, interactions between representative APC: erucylphosphocholine, and artificial lipid raft system, modeled as Langmuir monolayer (composed of cholesterol and sphingomyelin mixed in 1:2 proportion) were investigated. The Langmuir monolayer experiments, based on recording surface pressure-area isotherms, were complemented with Brewster angle microscopy results, which enabled direct visualization of the monolayers structure. In addition, the investigated monolayers were transferred onto solid supports and studied with AFM. The interactions between model raft system and erucylphosphocholine were analyzed qualitatively (with mean molecular area values) as well as quantitatively (with ΔG(exc) function). The obtained results indicate that erucylphosphocholine introduced to raft-mimicking model membrane causes fluidizing effect and weakens the interactions between cholesterol and sphingomyelin, which results in phase separation at high surface pressures. This leads to the redistribution of cholesterol molecules in model raft, which confirms the results observed in biological studies.
Collapse
Affiliation(s)
- Anita Wnętrzak
- a Institute of Physics, Jagiellonian University , Łojasiewicza, Kraków and
| | - Kazimierz Łątka
- a Institute of Physics, Jagiellonian University , Łojasiewicza, Kraków and
| | | | - Joanna Zemla
- a Institute of Physics, Jagiellonian University , Łojasiewicza, Kraków and
| | | |
Collapse
|
4
|
Kostadinova A, Topouzova-Hristova T, Momchilova A, Tzoneva R, Berger MR. Antitumor Lipids--Structure, Functions, and Medical Applications. Adv Protein Chem Struct Biol 2015; 101:27-66. [PMID: 26572975 DOI: 10.1016/bs.apcsb.2015.08.001] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Cell proliferation and metastasis are considered hallmarks of tumor progression. Therefore, efforts have been made to develop novel anticancer drugs that inhibit both the proliferation and the motility of tumor cells. Synthetic antitumor lipids (ATLs), which are chemically divided into two main classes, comprise (i) alkylphospholipids (APLs) and (ii) alkylphosphocholines (APCs). They represent a new entity of drugs with distinct antiproliferative properties in tumor cells. These compounds do not interfere with the DNA or mitotic spindle apparatus of the cell, instead, they incorporate into cell membranes, where they accumulate and interfere with lipid metabolism and lipid-dependent signaling pathways. Recently, it has been shown that the most commonly studied APLs inhibit proliferation by inducing apoptosis in malignant cells while leaving normal cells unaffected and are potent sensitizers of conventional chemo- and radiotherapy, as well as of electrical field therapy. APLs resist catabolic degradation to a large extent, therefore accumulate in the cell and interfere with lipid-dependent survival signaling pathways, notably PI3K-Akt and Raf-Erk1/2, and de novo phospholipid biosynthesis. They are internalized in the cell membrane via raft domains and cause downstream reactions as inhibition of cell growth and migration, cell cycle arrest, actin stress fibers collapse, and apoptosis. This review summarizes the in vitro, in vivo, and clinical trials of most common ATLs and their mode of action at molecular and biochemical levels.
Collapse
Affiliation(s)
- Aneliya Kostadinova
- Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Sofia, Bulgaria.
| | | | - Albena Momchilova
- Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Sofia, Bulgaria
| | - Rumiana Tzoneva
- Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Sofia, Bulgaria.
| | - Martin R Berger
- German Cancer Research Center, Toxicology and Chemotherapy Unit, Heidelberg, Germany
| |
Collapse
|
5
|
de Sá MM, Rangel-Yagui CO. Molecular Determinants for the Binding Mode of Alkylphosphocholines in the C2 Domain of PKCα. Mol Inform 2015; 34:84-96. [PMID: 27490031 DOI: 10.1002/minf.201400104] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2014] [Accepted: 11/14/2014] [Indexed: 11/10/2022]
Abstract
Alkylphosphocholines (APCs) and alkyl-lysophosphocholines (ALPs) are antineoplastic agents that interfere with cellular membranes and signaling proteins. Protein kinase Cα (PKCα) is a signaling protein composed by catalytic (C3, C4) and regulatory domains (C1, C2). The C2 needs calcium (Ca(2+) ) and phosphatidylserine (PS) for activation. Miltefosine inhibits PKCα competitively with regard to PS and non-competitively with regard to Ca(2+) , however, the mechanism of action is unknown. We employed molecular docking, molecular dynamics and chemometric methods to verify how 7 APCs and ALPs derivatives and PS interact with the C2 domain. All ligands except PS were grouped in 2 clusters according to their interactions inside the enzyme. The findings showed that PS's phosphoryl oxygens interact with Ca(2+) , the serine moiety interacts with Asn189, and the carbonyl oxygen of the alkylic chain interacts with Arg249 and Thr251. On the other hand, ligands' phosphoryl oxygens interact with Asn189, Arg249, Thr250, and one water molecule instead of Ca(2+) . Because of the different binding mode, we hypothesize that the ligands cause conformational changes in the calcium binding region. Moreover, the packing mismatch between bilayer-forming lipids and ALP/APC chain impedes the C2 domain from docking to the internal leaflet of cellular membranes, interrupting PKCα activation.
Collapse
Affiliation(s)
- Matheus M de Sá
- Department of Pharmacy, University of São Paulo, Avenida Professor Lineu Prestes, 580, 05508-900, São Paulo, SP, Brazil. , .,Laboratório de Genética e Cardiologia Molecular, Instituto do Coração (InCor), Faculdade de Medicina da Universidade de São Paulo, Avenida Dr Eneas de Carvalho Aguiar, 44, 10th floor, 05403-000, São Paulo, SP, Brazil phone:+55 11 2661 5511. ,
| | - Carlota O Rangel-Yagui
- Department of Pharmaceutical and Biochemical Technology, University of São Paulo, Avenida Professor Lineu Prestes, 580, 05508-900, São Paulo, SP, Brazil
| |
Collapse
|
6
|
Yosifov DY, Kaloyanov KA, Guenova ML, Prisadashka K, Balabanova MB, Berger MR, Konstantinov SM. Alkylphosphocholines and curcumin induce programmed cell death in cutaneous T-cell lymphoma cell lines. Leuk Res 2013; 38:49-56. [PMID: 24225136 DOI: 10.1016/j.leukres.2013.10.011] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2013] [Revised: 10/07/2013] [Accepted: 10/15/2013] [Indexed: 11/25/2022]
Abstract
While most patients with early-stage cutaneous T-cell lymphomas (CTCL) have a very good prognosis, the survival of patients with extensive tumour stage and visceral involvement remains extremely poor and necessitates the development of more effective treatment modalities. In this study, we evaluated the in vitro effects of two alkylphosphocholines (APCs, miltefosine and erufosine) and the polyphenolic compound curcumin on 5 human CTCL cell lines (Hut-78, HH, MJ, My-La CD4+ and My-La CD8+). All tested drugs showed considerable cytotoxic activity, as determined by the MTT dye reduction assay. The IC50 values of both APCs ranged from the low micromolar level (Hut-78 cells) to 60-80μM (HH cells). The IC50 values of curcumin ranged from 12 to 24μM. All tested drugs induced apoptosis, as ascertained by morphological changes, DNA fragmentation and activation of caspase cascades. Miltefosine and erufosine induced dephosphorylation of Akt in My-La CD8+ cells and phosphorylation of JNK in Hut-78 and My-La CD8+ cells. APCs increased the level of the autophagic marker LC3B in Hut-78 and MJ cells. Results from co-treatment with autophagy modulators suggested that the cytotoxicity of APCs in CTCL cells is mediated, at least in part, by induction of autophagy.
Collapse
Affiliation(s)
- Deyan Y Yosifov
- Laboratory for Experimental Chemotherapy, Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria; Center of Excellence - Translational Research in Haematology, National Specialised Hospital for Active Treatment of Haematological Diseases, Sofia, Bulgaria.
| | - Kaloyan A Kaloyanov
- Laboratory for Experimental Chemotherapy, Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria
| | - Margarita L Guenova
- Center of Excellence - Translational Research in Haematology, National Specialised Hospital for Active Treatment of Haematological Diseases, Sofia, Bulgaria; Laboratory of Haematopathology and Immunology, National Specialised Hospital for Active Treatment of Haematological Diseases, Sofia, Bulgaria
| | - Kamelia Prisadashka
- Department of Dermatology and Venereology, Medical Faculty, Medical University of Sofia, Sofia, Bulgaria
| | - Maria B Balabanova
- Department of Dermatology and Venereology, Medical Faculty, Medical University of Sofia, Sofia, Bulgaria
| | - Martin R Berger
- Toxicology and Chemotherapy Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Spiro M Konstantinov
- Laboratory for Experimental Chemotherapy, Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria; Center of Excellence - Translational Research in Haematology, National Specialised Hospital for Active Treatment of Haematological Diseases, Sofia, Bulgaria
| |
Collapse
|
7
|
Lukáč M, Mrva M, Garajová M, Mojžišová G, Varinská L, Mojžiš J, Sabol M, Kubincová J, Haragová H, Ondriska F, Devínsky F. Synthesis, self-aggregation and biological properties of alkylphosphocholine and alkylphosphohomocholine derivatives of cetyltrimethylammonium bromide, cetylpyridinium bromide, benzalkonium bromide (C16) and benzethonium chloride. Eur J Med Chem 2013; 66:46-55. [PMID: 23792315 DOI: 10.1016/j.ejmech.2013.05.033] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2013] [Revised: 05/21/2013] [Accepted: 05/22/2013] [Indexed: 01/29/2023]
Abstract
A series of alkylphosphocholine and alkylphosphohomocholine derivatives of cetyltrimethylammonium bromide, cetylpyridinium bromide, benzalkonium bromide (C16) and benzethonium chloride have been synthesized. Their physicochemical properties were also investigated. The critical micelle concentration (cmc), the surface tension value at the cmc (γcmc), and the surface area at the surface saturation per head group (Acmc) were determined by means of surface tension measurements. The prepared compounds exhibit significant cytotoxic, antifungal and antiprotozoal activities. Alkylphosphocholines and alkylphosphohomocholines possess higher antifungal activity against Candida albicans in comparison with quaternary ammonium compounds in general. However, quaternary ammonium compounds exhibit significantly higher activity against human tumor cells and pathogenic free-living amoebae Acanthamoeba lugdunensis and Acanthamoeba quina compared to alkylphosphocholines. The relationship between structure, physicochemical properties and biological activity of the tested compounds is discussed.
Collapse
Affiliation(s)
- Miloš Lukáč
- Department of Chemical Theory of Drugs, Faculty of Pharmacy, Comenius University, Kalinčiakova 8, 832 32 Bratislava, Slovakia.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|